Mission

SeroScience LTD was founded in 2006 by a group of world renowned scientists to help pharma and medical device companies overcome adverse immunological responses to their products, with a particular focus on predicting and preventing hypersensitivity reactions to IV administered drugs as well as efficacy reduction due to anti-drug antibody build up to these drugs. It is the world's leading laboratory for the study of Complement Activation Related Pseudo Allergy (CARPA), a potentially lethal reaction to IV administered nanobiopharmaceuticals, and is responsible for the majority (40+) of peer reviewed articles on the subject to date.

Since then, SeroScience has expanded to offer a wider array of services in the toxicological and immunological sciences space, combining access to state-of-the-art GLP laboratories with consultation by a network of leading international experts in immunology, toxicology, and drug delivery.

Get in touch

At SeroScience, we know that finding the right laboratory is a choice not to be taken lightly. That’s why we offer free consultations to walk you through your needs, the scope of your goals, and your budget.

Book a Consultation ▸

Keywords:

predictive immunotoxicity, adverse immunological side effects, complement activation, Basophil Activation, pseudo allergy, preventing hypersensitivity reactions, predicting hypersensitivity reactions, serious adverse events, immune activation by nano-biopharmaceuticals, Cytokine Storm Syndrome, Accelerated Blood Clearance

CEO, Co-Founder

János Szebeni

Dr. János Szebeni, MD, PhD, DSc, Med. Habil., immunologist, co-founder and CEO of SeroScience Ltd. is also director of the Nanomedicine Research and Education Center at Semmelweis University in Budapest and full professor of immune biology at Miskolc University in Miskolc, Hungary. He has held various guest professor and scientific positions in Hungary and the United States where he lived for 22 years. In the US he worked, among others, at the University of Arizona, NCI/NIH, Walter Reed Army Institute of Research, and Harvard University. His research on various themes in hematology, membrane biology and immunology resulted in over 200 publications including peer-reviewed papers, book chapters, patents, and sole- or co-editorship in the books entitled “The Complement System: Novel Roles in Health and Disease” (Kluwer, 2004) and “Immune Aspects of Biopharmaceuticals and Nanomedicines” (Pan Stanford Series on Nanomedicine Vol. 3, 2018). He was primary investigator in more than a dozen European and Hungarian research grants and over 30 CRO projects over the past 15 years. Dr. Szebeni is a regular speaker at international conferences and seminars with over 60 presentations in the past five years. He is also an ad hoc consultant for the United States Food and Drug Administration (FDA). Three fields stand out where he has been most active: artificial blood, liposomes and the complement system. His original work led to the CARPA concept, i.e., that complement activation underlies numerous drug-induced (pseudo)allergic infusion reactions. CARPA has been included in a recent European Medicines Agency (EMA) guideline as a recommended preclinical safety test.

President

Tibor Héjj

Dr. Tibor Héjj, President of the SeroScience Group and responsible for its international sales and operations, is also the Founder and Managing Partner of Proactive Management Consulting (PMC) Ltd., a boutique strategy consulting firm specializing in supporting international operations and communications for multinational companies. He holds an MBA from Vanderbilt University, two M.Sc. degrees from the Technical University of Budapest, and a PhD in management theory from Sophia University in Italy.

Before founding PMC, Dr. Hejj was Country Manager for the Boston Consulting Group (1994-2001) and a Partner/International Vice President at A.T. Kearney (2001-2003). Earlier in his career, he co-founded and served for 10 years as one of the Executive Vice Presidents of Műszertechnika, the most successful Hungarian computer and telecom company of its time, with subsidiaries in Germany, Switzerland, USA and Taiwan.

Co-Director

László Rosivall

Dr. László Rosivall, MD, PhD, DSC Co-Director László Rosivall, MD, PhD, DSC, full professor, is co-founder of SeroScience Ltd. Dr. Rosivall is currently head of the International Nephrology Research and Training Center, and the PhD School of Basic Medical Sciences at Semmelweis University. He is former head of Department of Pathophysiology, and has also served as Rector of the Semmelweis University. During his extensive academic and teaching career, among other things, Dr. Rosivall pioneered recognizing and characterizing the intrarenal renin-angiotensin system (RAS). Using nanotechnology he visualized the glomerular filration rate (GFR) in vivo and discovered a new, short loop feedback mechanism in its regulation, which refined fundamental knowledge of several basic renal physiological issues. He is also a Széchenyi prize laurate.

Head of Research (in vivo)

Rudolf Urbanics

Dr. Rudolf Urbanics, MD, PhD, Head of the SeroScience in vivo laboratory, obtained his MD at Semmelweis Medical School, and his PhD degree at the Hungarian Academy of Sciences. Dr. Urbanics held teaching and research positions at the Semmelweis University and held various research positions at the Max Planck Society, Institute of Systemic Physiology in Dortmund, Germany, at the University of Pennsylvania, Philadelphia, at Pennsylvania Muscle Institute, and at the Central Nervous System Research Department of Knoll AG. His work encompassed the field of CNS regulation of blood flow/metabolism, ischemic/hypoxic disorders, stroke and chronic neurodegenerative disease models. He was Deputy R&D Director and Head of CNS Pharmacology at Biorex Ltd., in Budapest, Hungary and also worked at IVAX/Drug Research Institute Budapest, as Scientific Advisor and Leading Researcher in Safety and CNS Pharmacology. He was head of the In vivo Pharmacology group of TEVA in Budapest.

Head of Research (in vitro)

Gergely Tibor Kozma

Gergely Tibor Kozma, MSc, PhD, immunologist, is head of research of the in vitro laboratory of SeroScience Ltd., Budapest, Hungary. He obtained his PhD in immunology and molecular biology at Semmelweis University. He worked at Semmelweis University as well as several private companies as a researcher studying the immunological mechanisms of allergy and nano-drug induced hypersensitivity. Dr. Kozma spent 1.5 years in Rome, Italy as a postdoctoral researcher sponsored by the Marie Curie Research Training Network to investigate the antigen presenting processes of dendritic cells. In addition to research, he was also involved in assay development in the field of monoclonal antibody production, ELISAs and protein engineering in E. coli. He is also a specialist of immune cells phenotyping by flow cytometry. His current field of research is the immunological study of nano-drug induced hypersensitivity reactions primarily complement activation related processes and immunogenicity. He has co-authored 20 original papers, with more than 700 citations.

Attorney-at-law, Chief Operating Officer

János Matuz

Dr. János Matuz participated in several due diligence projects focusing on multinationals, public companies and SMEs. He actively contributed to projects with the aim of organizational development and process restructuring. As a project manager he continuously leads projects with the magnitude of >10MEUR. In other cases, as a project monitor, he supervises their realization. János led the preparation phase of several projects financed by national, EU or Swiss Contribution funds. He participated in the creation of concepts and their feasibility studies, furthermore, in the preparation of the full tender documentation. He has been dealing with technology transfer, innovation management, and the development and improvement of clusters for about 10 years. János is an active attorney-at-law in the field of civil law, competition law and company law.

Project Manager, Researcher

Tamás Mészáros

Tamás Mészáros, MSc, PhD, is a research fellow at SeroScience Ltd., Budapest, Hungary since 2009. He received his MSc degree as an immunologist from Eötvös Lóránd University, Budapest, Hungary in the same year and his PhD degree at Semmelweis University. He is working on CRO projects, specifically in vitro research and development. His current field of research is the immunological study of nano-drug induced hypersensitivity reactions primarily complement activation related processes and immunogenicity. His special skills include in vitro ELISA assays and techniques. He has co-authored 20 original papers, with more than 100 citations.